Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 8/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 6/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL2420627 | 0.98 | CYP2A6 (0.48) | CYP2A6CHRNB2CHRNA4CYP11B2CHRNA7 | |
| SCHEMBL10474789 | 0.92 | CYP11B2 (0.52) | CYP2A6CHRNB2CHRNA4CYP11B2CHRNA7 | |
| SCHEMBL17977193 | 0.81 | CYP2A6 (0.44) | CYP2A6CHRNB2CHRNA4CYP11B2CHRNA7 | |
| SCHEMBL10685177 | 0.77 | CYP11B1 (0.49) | CYP2A6CYP11B2MEN1CYP2D6KMT2A | |
| SCHEMBL10685837 | 0.77 | CHRNA7 (0.44) | CYP2A6CHRNA7CYP2D6CYP1A2 | |
| SCHEMBL2540209 | 0.77 | LMNA (0.60) | CYP11B2SMN1; SMN2 | |
| SCHEMBL2534029 | 0.77 | KIF11 (0.49) | KMT2APOLBSMN1; SMN2 | |
| SCHEMBL10685181 | 0.77 | CYP11B1 (0.49) | CYP2A6CYP11B2MEN1CYP2D6KMT2A | |
| SCHEMBL4672270 | 0.77 | — | — | |
| SCHEMBL4478683 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11851425-B2 | Combination treatments comprising administration of 1H-pyrazolo[4,3-B]pyridines | H. LUNDBECK A/S (DK) | 2023-12-26 | — | — | US | disclosed |
| CN-111556871-B | 1H-pyrazolo [4,3-b ] pyridines as PDE1 inhibitors | H.隆德贝克有限公司 | 2023-07-07 | — | — | CN | disclosed |
| US-11634416-B2 | Combination treatments comprising administration of 1H-pyrazolo[4,3-b]pyridines | H. LUNDBECK A/S (DK) | 2023-04-25 | — | — | US | disclosed |
| US-11491140-B2 | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2022-11-08 | — | — | US | disclosed |
| CN-111465410-B | Combination therapy comprising administration of 1H-pyrazolo [4,3-B ] pyridine | H.隆德贝克有限公司 | 2022-10-25 | — | — | CN | disclosed |
| CN-111526890-B | Combination therapy comprising administration of 1H-pyrazolo [4,3-B ] pyridine | H.隆德贝克有限公司 | 2022-10-14 | — | — | CN | disclosed |
| EP-3723808-B1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES | H LUNDBECK AS (DK) | 2021-10-20 | — | — | EP | disclosed |
| EP-3723808-B1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES | H LUNDBECK AS (DK) | 2021-10-20 | — | — | EP | disclosed |
| EP-3723807-B1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES | H LUNDBECK AS (DK) | 2021-10-20 | — | — | EP | disclosed |
| EP-3723807-B1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES | H LUNDBECK AS (DK) | 2021-10-20 | — | — | EP | disclosed |
| WO-2012097682-A1 | BICYCLIC INHIBITORS OF ALK | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | WO | disclosed |
| EP-2374802-A1 | KYNURENINE PRODUCTION INHIBITOR | Kyowa Hakko Kirin Co., Ltd. (JP) | 2011-10-12 | — | — | EP | disclosed |
| US-20110237584-A1 | KYNURENINE PRODUCTION INHIBITOR | KYOWA KIRIN CO., LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
| US-7763617-B2 | Pyrazolopyridine-4-yl pyridazinone derivatives and addition salts thereof, and PDE inhibitors comprising the same derivatives or salts as active ingredient | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2010-07-27 | — | — | US | disclosed |
| CN-100575346-C | Pyrimidone derivatives is acute and chronic inflammatory, ischemia and reconstruction capability pathology as the medicine treatment | BAYER HEALTHCARE AG | 2009-12-30 | — | — | CN | disclosed |
| US-20080207902-A1 | Pyrazolopyridine-4-Yl Pyridazinone Derivatives and Addition Salts Thereof, and Pde Inhibitors Comprising the Same Derivatives or Salts as Active Ingredient | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2008-08-28 | — | — | US | disclosed |
| CN-101189230-A | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (CH) | 2008-05-28 | — | — | CN | disclosed |
| CN-100378072-C | Heterocyclic methyl sulfone derivative | DAIICHI SEIYAKU CO (JP) | 2008-04-02 | — | — | CN | disclosed |
| CN-1732159-A | Pyrimidinone derivatives as therapeutic agents for the treatment of acute and chronic inflammatory, ischemic and remodelling pathologies | BAYER HEALTHCARE AG (DE) | 2006-02-08 | — | — | CN | disclosed |
| EP-0315839-A2 | 3-Substituted pyridines | NIHON BAYER AGROCHEM K.K. (JP) | 1989-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11851425-B2 | Combination treatments comprising administration of 1H-pyrazolo[4,3-B]pyridines | PDE3B, PDE1B, PDE12 | CYP2A6 948/4885CHRNB2 32/4885CHRNA4 38/4885 |
| US-11491140-B2 | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors | PDE3A, PDE5A, PDE12 | CYP2A6 816/4885CHRNB2 134/4885CHRNA4 119/4885 |
| US-11634416-B2 | Combination treatments comprising administration of 1H-pyrazolo[4,3-b]pyridines | PDE1B, PDE3B, PDE1A | CYP2A6 331/4885CHRNB2 68/4885CHRNA4 48/4885 |
| US-20080207902-A1 | Pyrazolopyridine-4-Yl Pyridazinone Derivatives and Addition Salts Thereof, and Pde Inhibitors Comprising the Same Derivatives or Salts as Active Ingredient | PDE5A, PDE3A, PDE3B | CYP2A6 295/4885CHRNB2 1925/4885CHRNA4 1265/4885 |
| US-20110237584-A1 | KYNURENINE PRODUCTION INHIBITOR | KYNU, KMO, IDO1 | CYP2A6 478/4885CHRNB2 1531/4885CHRNA4 1541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.